UCB (OTCMKTS:UCBJF) Sets New 1-Year High – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $322.94 and last traded at $322.94, with a volume of 40 shares traded. The stock had previously closed at $316.84.

Analyst Ratings Changes

UCBJF has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, December 8th. Stephens reiterated an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Finally, Barclays reissued an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, UCB has a consensus rating of “Buy”.

UCB Stock Up 1.9%

The firm has a fifty day moving average price of $295.03 and a two-hundred day moving average price of $268.27. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.